For an extended period after initial founding, PEEL Therapeutics functioned in stealth mode. The firm is structured around development of a cancer care platform designed to deliver anti-cancer protein nano-particles -- particles that regulate cellular response to environmental stresses by stimulating transcription of genes involved in cell cycle arrests, cell death and metabolisms, enabling physicians to treat and to cure cancer in humans. The word "Peel" in the firm's name - interestingly speaks to what likely makes the firm of interest. "Peel" is the phonetic spelling of the Hebrew word for elephant - and use of the term serves to reveal a very different and important aspect of the firm's work -- and the fact that it is anchored in study of p53 - a well-known tumor suppressor protein - which the pachyderm has in far greater quality than human along with a mortality rate from cancer that is a small fraction of that found in huma
